Video

Giora Sharf Discusses Intentional, Unintentional Nonadherence in CML Patients

Although there is a clear link between nonadherence and outcomes of a patient with chronic myelogenous leukemia (CML), some patient intentionally stop taking their medication, said Giora Sharf, co-founder of the CML Advocates Network.

Although there is a clear link between nonadherence and outcomes of a patient with chronic myelogenous leukemia (CML), some patient intentionally stop taking their medication, said Giora Sharf, co-founder of the CML Advocates Network.

Some patients are unintentionally not adhering to their medication, sometimes because they simply forget, which the CML Advocates Network hopes combat through its new app.

However, there are times patients choose intentional nonadherence, often because the patient does not want to suffer from the side effects of the medication. Another dangerous barrier is when a patient feels fine, and stops treatment because he or she doesn’t see the point in taking it, Mr Sharf explained.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Hamlet Gasoyan, PhD
EHA 2025 Congress Recap | Image Credit: Venngage
Coral Omene, MD, PhD, sitting for a vieo interview
Lorna Warwick
Ashley Yocum, PhD
Dr Matthew Matasar
Dr Xavier Leleu
Francesco Sparano, MSc
Dr Marina Kremskayana
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo